Michigan Rise Pre-Seed Fund provides early-stage funding, seed investment, and gap funding to technology startups to help commercialize innovative technologies.
Banner-2.jpg

Startup Investment News & Pre-Seed Fund Portfolio Updates

Startup Investment News & Pre-Seed Fund Portfolio Updates

 
MICHIGAN RISE INVESTS IN MAGSORBEO BIOMEDICAL, DEVELOPER OF FULLY ABSORBABLE ORTHOPEDIC IMPLANTS

EAST LANSING, Mich. –– Michigan Rise has expanded its life science and medical device portfolio with an investment in Magsorbeo Biomedical, an orthopedic medical device startup based in Detroit and East Lansing. The company is developing advanced bioabsorbable implants from Curasorb, its proprietary magnesium alloy developed in partnership with Terves Inc. which is designed to be safely absorbed by the body over time, with the goal of reducing surgical interventions, improving patient quality of life and outcomes, and lowering healthcare costs.

Read More
Nichole Maguire
MICHIGAN RISE FUNDS BLUECONDUIT, TECHNOLOGY THAT IDENTIFIES LEAD SERVICE LINES AND PREVENTS LEAD CONTAMINATION IN WATER SYSTEMS

EAST LANSING, Mich. –– Michigan Rise has expanded its portfolio in GovTech and CleanTech with an investment in BlueConduit, headquartered in Ann Arbor. BlueConduit has developed an innovative SaaS platform that uses predictive modeling to accurately identify lead service lines (LSL). The platform provides automated reporting tools for municipalities to fulfill mandatory reporting requirements set by the Environmental Protection Agency (EPA).  

Read More
Nichole Maguire
Michigan Rise Funds Throdle, the All-In-One Social Platform for Car Enthusiasts

EAST LANSING, Mich. –– Michigan Rise has added Throdle, Inc. to its growing portfolio in the information technology sector. Based in Ypsilanti, Throdle is a social media plus platform facilitating a digital community for car enthusiasts who primarily meet at physical events. The platform provides event push notification features and much more. Throdle aims to bring a $28B market online, centralizing forums and gatherings for car enthusiasts and helping advertisers reach them.

Read More
Nichole Maguire
Michigan Rise Funds FreightRoll, Inc. Logistics Automation Solution

Michigan Rise has announced an investment in FreightRoll, Inc. during the company's pre-seed extension round. FreightRoll has developed Digital Guard, an automated solution that offers a paperless alternative to traditional full-time warehouse gate attendants. This technology streamlines the authentication and entry process for truck drivers and shipments, allowing companies to reduce overhead costs and enhance operational efficiency.

Read More
Doug Snitgen
Michigan Rise Supports the Development of Therapy for Atrial Fibrillation (A-Fib) with investment in MediCool Technologies

Michigan Rise has expanded its life sciences portfolio with an investment in medical device company, MediCool Technologies. The Traverse City based company is developing a painless and potentially more effective implantable cardioversion device for treating atrial fibrillation (A-Fib), the most common heart arrhythmia, affecting over 6 million people in the United States.

Read More
Doug Snitgen
Gilead and EVOQ Therapeutics Announce Collaboration to Advance Immunotherapies

FOSTER CITY, Calif. & ANN ARBOR, Mich.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and EVOQ Therapeutics, Inc. (EVOQ) today announced a collaboration and  licensing agreement to advance EVOQ’s proprietary technology for the treatment of rheumatoid arthritis (RA) and lupus. EVOQ’s NanoDisc technology is designed to enable lymph targeted delivery of disease-specific antigens and has the potential to change the paradigm for the treatment of autoimmune diseases.

Read More
Nichole Maguire
EVOQ Announces JDRF Collaboration to Develop its Novel Platform Technology in Type 1 Diabetes

ANN ARBOR, Mich., December 13, 2022 – EVOQ Therapeutics, Inc. (EVOQ), a biopharmaceutical company focused on the discovery and development of drugs to treat patients afflicted with autoimmune diseases, today announced a collaboration with JDRF for the development of a new drug platform for antigen-specific immune-tolerizing therapy against Type 1 diabetes (T1D).

Read More
Nichole Maguire
Genomenon Provides Genomic Data on 450 Diseases to Advance Early Identification of Rare Disease in Newborns

Genomenon®, Inc., an AI-driven genomics company, announced more details on their plan to curate the genes associated with over 450 rare diseases for the purpose of newborn screening via next generation DNA sequencing. The program is the first initiative in Genomenon’s mission to curate the entire human genome and is an essential part of the BeginNGS™ newborn sequencing project led by Rady Children’s Institute for Genomic Medicine (RCIGM).

Read More
Nichole Maguire